Search

Your search keyword '"Ray-Coquard, Isabelle"' showing total 2,289 results
Start Over Author "Ray-Coquard, Isabelle"
2,289 results on '"Ray-Coquard, Isabelle"'

251. Endometrial carcinosarcoma

Author

Bogani, Giorgio, primary, Ray-Coquard, Isabelle, additional, Concin, Nicole, additional, Ngoi, Natalie Yan Li, additional, Morice, Philippe, additional, Caruso, Giuseppe, additional, Enomoto, Takayuki, additional, Takehara, Kazuhiro, additional, Denys, Hannelore, additional, Lorusso, Domenica, additional, Coleman, Robert, additional, Vaughan, Michelle M, additional, Takano, Masashi, additional, Provencher, Diane Michele, additional, Sagae, Satoru, additional, Wimberger, Pauline, additional, Póka, Robert, additional, Segev, Yakir, additional, Kim, Se Ik, additional, Kim, Jae-Weon, additional, Candido dos Reis, Francisco Jose, additional, Ramirez, Pedro T, additional, Mariani, Andrea, additional, Leitao, Mario, additional, Makker, Vicky, additional, Abu-Rustum, Nadeem R, additional, Vergote, Ignace, additional, Zannoni, Gianfranco, additional, Tan, David, additional, McCormack, Mary, additional, Paolini, Biagio, additional, Bini, Marta, additional, Raspagliesi, Francesco, additional, Benedetti Panici, Pierluigi, additional, Di Donato, Violante, additional, Muzii, Ludovico, additional, Colombo, Nicoletta, additional, Pignata, Sandro, additional, Scambia, Giovanni, additional, and Monk, Bradley J, additional

Published
2022
Full Text
View/download PDF

252. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS

Author

Chvetzoff, Gisèle, primary, Bouleuc, Carole, additional, Lardy-Cléaud, Audrey, additional, Saltel, Pierre, additional, Dieras, Véronique, additional, Morelle, Magali, additional, Guastalla, Jean-Paul, additional, Tredan, Olivier, additional, Rebattu, Paul, additional, Pop, Simona, additional, Ray-Coquard, Isabelle, additional, Pierga, Jean-Yves, additional, Mignot, Laurent, additional, Laurence, Valérie, additional, Bourne-Branchu, Valérie, additional, Pérol, David, additional, and Bachelot, Thomas, additional

Published
2022
Full Text
View/download PDF

253. Patterns of care and outcome of CIC ‐rearranged sarcoma patients: A nationwide study of the French sarcoma group

Author

Brahmi, Mehdi, primary, Gaspar, Nathalie, additional, Gantzer, Justine, additional, Toulmonde, Maud, additional, Boudou‐Rouquette, Pascaline, additional, Bompas, emmanuelle, additional, Firmin, Nelly, additional, Valentin, Thibaud, additional, Cancel, Mathilde, additional, Duffaud, Florence, additional, Bertucci, Francois, additional, Perrin, Christophe, additional, Dufresne, Armelle, additional, Marec‐Bérard, Perrine, additional, Jean‐Denis, Myriam, additional, Ray‐Coquard, Isabelle, additional, Le Loarer, Francois, additional, Pierron, Gaille, additional, Tirode, Franck, additional, Blay, Jean‐Yves, additional, and Watson, Sarah, additional

Published
2022
Full Text
View/download PDF

254. Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group

Author

Mourksi, Nour‐El‐Houda, primary, Dalban, Cécile, additional, Colombe‐Vermorel, Amélie, additional, Odeyer, Laetitia, additional, Simioni, Valentin, additional, Frenel, Jean‐Sébastien, additional, Fabbro, Michel, additional, Bazan, Fernando, additional, Abadie‐Lacourtoisie, Sophie, additional, Coquan, Elodie, additional, Martinez, Séverine, additional, Garin, Gwenaelle, additional, Tabone‐Eglinger, Séverine, additional, Treilleux, Isabelle, additional, Chabaud, Sylvie, additional, Pérol, David, additional, Ray‐Coquard, Isabelle, additional, Heudel, Pierre‐Etienne, additional, Diaz, Jean‐Jacques, additional, and Marcel, Virginie, additional

Published
2022
Full Text
View/download PDF

255. O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775

Author

Makker, Vicky, primary, Colombo, Nicoletta, additional, Herráez, Antonio Casado, additional, Monk, Bradley, additional, Mackay, Helen, additional, Santin, Alessandro, additional, Miller, David, additional, Moore, Richard, additional, Ray-Coquard, Isabelle, additional, Shapira-Frommer, Ronnie, additional, Ushijima, Kimio, additional, Yonemori, Kan, additional, Kim, Yong Man, additional, Alia, Eva Guerra, additional, Sanli, Ulus, additional, Xie, Ran, additional, Zale, Melissa, additional, Mckenzie, Jodi, additional, Barresi, Gianmaria, additional, and Lorusso, Domenica, additional

Published
2022
Full Text
View/download PDF

256. Expanding the molecular spectrum of tenosynovial giant cell tumors

Author

Gauduchon, Thibault, Vanacker, Helene, Pissaloux, Daniel, Cassier, Philippe, Dufresne, Armelle, Karanian, Marie, Meurgey, Alexandra, Bouhamama, Amine, Gouin, François, Ray-Coquard, Isabelle, Blay, Jean-Yves, Tirode, Franck, and Brahmi, Mehdi

Subjects
Cancer Research, Oncology
Abstract

BackgroundWhile great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge. The canonical oncogenic fusion CSF1::COL6A3 is not systematically observed, suggesting that other oncogenic mechanisms are involved in tumorigenesis. This study aims to explore by RNA sequencing a retrospective series of tumors diagnosed as TGCT, in order to provide a better description of their molecular landscape and to correlate molecular features with clinical data.MethodsWe analyzed clinicopathological data and performed whole-exome RNA sequencing on 41 TGCT samples.ResultsRNAseq analysis showed significant higher CSF1 and CSF1-R expression than a control panel of 2642 solid tumors. RNA sequencing revealed fusion transcripts in 14 patients including 6 not involving CSF1 and some previously unreported fusions. Unsupervised clustering on the expression profiles issued from this series suggested two distinct subgroups: one composed of various molecular subtypes including CSF1 and FN1 rearranged samples and one composed of four tumors harboring an HMGA2::NCOR2 fusion, suggesting distinct tumor entities. Overall, 15 patients received at least one systemic anti-CSF1R treatment and clinical improvement was observed in 11 patients, including patients from both clusters.DiscussionThis study reported molecular heterogeneity in TGCT, contrasting with the clinical and pathological homogeneity and the ubiquitous high CSF1 and CSF1R expression levels. Whether molecular diversity may impact the efficacy of systemic treatments needs to be further investigated.

Published
2022

258. Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort

Author

Roth, Gaël S., primary, Fayet, Yohan, additional, Benmameche-Medjahed, Sakina, additional, Ducimetière, Françoise, additional, Charreton, Amandine, additional, Cropet, Claire, additional, Chabaud, Sylvie, additional, Marion-Audibert, Anne-Marie, additional, Berthelet, Olivier, additional, Walter, Thomas, additional, Adham, Mustapha, additional, Baconnier, Mathieu, additional, Tavan, David, additional, Williet, Nicolas, additional, Artru, Pascal, additional, Huet-Penz, Floriane, additional, Ray-Coquard, Isabelle, additional, Farsi, Fadila, additional, Labrosse, Hélène, additional, and de la Fouchardière, Christelle, additional

Published
2022
Full Text
View/download PDF

259. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group

Author

Croce, Sabrina, primary, Devouassoux-Shisheboran, Mojgan, additional, Pautier, Patricia, additional, Ray-Coquard, Isabelle, additional, Treilleux, Isabelle, additional, Neuville, Agnès, additional, Arnould, Laurent, additional, Just, Pierre-Alexandre, additional, Belda, Marie Aude Le Frere, additional, Averous, Gerlinde, additional, Leroux, Agnès, additional, Mery, Eliane, additional, Loussouarn, Delphine, additional, Weinbreck, Nicolas, additional, Le Guellec, Sophie, additional, Mishellany, Florence, additional, Morice, Philippe, additional, Guyon, Frédéric, additional, and Genestie, Catherine, additional

Published
2022
Full Text
View/download PDF

260. 2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers

Author

Leman, Raphaël, primary, Muller, Etienne, additional, Goardon, Nicolas, additional, Chentli, Imène, additional, Tranchant, Aurore, additional, Legros, Angelina, additional, Castera, Laurent, additional, Morel, Alain, additional, Brunet, Christel, additional, Bocly, Véronique, additional, Fernandez, Eric, additional, Coulet, Florence, additional, Genestie, Catherine, additional, Lück, Hans-Joachim, additional, Gargiulo, Piera, additional, González-Martin, Antonio, additional, Grimm, Christoph, additional, Ray-Coquard, Isabelle, additional, Pujade-Lauraine, Eric, additional, and Vaur, Dominique, additional

Published
2022
Full Text
View/download PDF

261. 2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial

Author

Christinat, Yann, primary, Ho, Liza, additional, Clément, Sophie, additional, Genestie, Catherine, additional, Sehouli, Jalid, additional, Martin, Antonio Gonzalez, additional, Denison, Ursula, additional, Fujiwara, Keiichi, additional, Vergote, Ignace, additional, Tognon, Germana, additional, Hietanen, Sakari, additional, Pujade-Lauraine, Eric, additional, Ray-Coquard, Isabelle, additional, and McKee, Thomas A, additional

Published
2022
Full Text
View/download PDF

262. 2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer

Author

Harter, Philipp, primary, Marmé, Frederik, additional, Pietzner, Klaus, additional, Reuss, Alexander, additional, Ray-Coquard, Isabelle, additional, Redondo, Andrés, additional, Oaknin, Ana, additional, Jonuskiene, Goda, additional, Lindemann, Kristina, additional, Kurzeder, Christian, additional, Huober, Jens, additional, van Nieuwenhuysen, Els, additional, Henry, Stephanie, additional, Marth, Christian, additional, Tsibulak, Irina, additional, Cron, Nadin, additional, and Pautier, Patricia, additional

Published
2022
Full Text
View/download PDF

263. 2022-RA-605-ESGO Long term quality of life after chemotherapy among rare ovarian cancer survivors: the national gineco case-controlVivrovaire Rare Tumorsstudy

Author

Joly, Florence, primary, Ray-Coquard, Isabelle Laure, additional, Floquet, Anne, additional, Lefèvre-Arbogast, Sophie, additional, Selle, Frederic, additional, Berton, Dominique, additional, Frank, Sophie, additional, Rouge, Thibault De La Motte, additional, Kalbacher, Elsa, additional, Provansal, Magali, additional, Lortholary, Alain, additional, Orfeuvre, Hubert, additional, Alexandre, Jerome, additional, Augereau, Paule, additional, Nadeau, Cédric, additional, Kurtz, Jean-Emmanuel, additional, Grellard, Jean-Michel, additional, Clarisse, Bénédicte, additional, Pautier, Patricia, additional, and Gernier, Francois, additional

Published
2022
Full Text
View/download PDF

264. 2022-RA-1551-ESGO Impact of age on first line treatments of ovarian cancer and their outcomes: results from the Unicancer ESME OVR real-world database

Author

Lefevre, Leïla Bengrine, primary, Fouquier, Anaïs, additional, Ray-Coquard, Isabelle, additional, Favier, Laure, additional, Joly, Florence, additional, Rodrigues, Manuel, additional, Sauterey, Baptiste, additional, Colombo, Pierre Emmanuel, additional, Floquet, Anne, additional, Leblanc, Eric, additional, Sabatier, Rene, additional, Barranger, Emmanuel, additional, Savoye, Aude-Marie, additional, Pautier, Patricia, additional, Petit, Thierry, additional, Classe, Jean-Marc, additional, Pomel, Christophe, additional, Bertaut, Aurelie, additional, Mourey, Loîc, additional, Bosquet, Lise, additional, and Falandry, Claire, additional

Published
2022
Full Text
View/download PDF

265. 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial

Author

Willing, Eva-Maria, primary, Vollbrecht, Claudia, additional, Voessing, Christine, additional, Weist, Peggy, additional, Schallenberg, Simon, additional, Jori, Balazs, additional, Tiemann, Markus, additional, Bataillon, Guillaume, additional, Harter, Philipp, additional, Pignata, Sandro, additional, Martin, Antonio Gonzales, additional, Vergote, Ignace, additional, Colombo, Nicoletta, additional, Marth, Christian, additional, Berg, Tobias, additional, Kah, Bettina, additional, Herbst, Johanna, additional, Noettrup, Trine Jakobi, additional, Falk, Markus, additional, Arndt, Kathrin, additional, Ray-Coquard, Isabelle, additional, Polten, Andreas, additional, Bernstein, Robert, additional, Selzam, Franziska, additional, Pirngruber, Judith, additional, Schmidt, Stefanie, additional, Hummel, Michael, additional, Sehouli, Jalid, additional, Horst, David, additional, Braicu, Elena Ioana, additional, Lauraine, Eric Pujade, additional, Tiemann, Katharina, additional, and Heukamp, Lukas C, additional

Published
2022
Full Text
View/download PDF

266. 2022-RA-703-ESGO Primary and interval debulking surgery in advanced ovarian cancer: real-world clinical outcomes of patients in 1st line setting, analysis from the french national ESME-unicancer database

Author

Costaz, Hélène, primary, Boussere, Amal, additional, Thomas, Quentin Dominique, additional, Ray-Coquard, Isabelle, additional, Pomel, Christophe, additional, Gladieff, Laurence, additional, Marchal, Frédéric Marchal, additional, Laas, Enora, additional, Rouzier, Roman, additional, Sabatier, Renaud, additional, Floquet, Anne, additional, Rouge, Thibault de la Motte, additional, Pautier, Patricia, additional, Leblanc, Eric, additional, Barranger, Emmanuel, additional, Petit, Thierry, additional, Fiteni, Frédéric, additional, Colombo, Pierre-Emmanuel, additional, Martin, Anne-Laure Martin, additional, and Classe, Jean-Marc, additional

Published
2022
Full Text
View/download PDF

267. 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775

Author

Lorusso, Domenica, primary, Makker, Vicky, additional, Herraez, Antonio Casado, additional, Monk, Bradley J, additional, Mackay, Helen, additional, Santin, Alessandro D, additional, Miller, David S, additional, Moore, Richard, additional, Baron-Hay, Sally, additional, Ray-Coquard, Isabelle, additional, Shapira-Frommer, Ronnie, additional, Ushijima, Kimio, additional, Yonemori, Kan, additional, Kim, Yong Man, additional, Guerra Alia, Eva M, additional, Sanli, Ulus A, additional, Huang, Jie, additional, McKenzie, Jodi, additional, Barresi, Gianmaria, additional, and Colombo, Nicoletta, additional

Published
2022
Full Text
View/download PDF

268. 2022-RA-823-ESGO FOXL2 mutation detection in circulating tumor DNA of adult granulosa cell tumors as a potential biomarker for disease monitoring from the randomized ALIENOR trial, a GINECO study

Author

Treilleux, Isabelle, primary, Lainé, Alexandra, additional, Combaret, Valérie, additional, Dalban, Cécile, additional, Gladieff, Laurence, additional, Chevalier, Hortense, additional, Provansal, Magali, additional, Kurtz, Jean-Emmanuel, additional, Brocard, Fabien, additional, Selle, Frédéric, additional, Heudel, Pierre Etienne, additional, Pautier, Patricia, additional, Fabbro, Michel, additional, Floquet, Anne, additional, Berton, Dominique, additional, Savoye, Aude-Marie, additional, Leheurteur, Marianne, additional, Kaminsky, Marie-Christine, additional, Chabaud, Sylvie, additional, and Ray-Coquard, Isabelle, additional

Published
2022
Full Text
View/download PDF

269. 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer

Author

Concin, Nicole, primary, Monk, Bradley J, additional, Mirza, Mansoor Raza, additional, Coleman, Robert L, additional, Ray-Coquard, Isabelle, additional, Pothuri, Bhavana, additional, Baurain, Jean-Francois, additional, Alejandro Perez-Fidalgo, J, additional, Cibula, David, additional, Saverse, Antonella, additional, Banerjee, Susana, additional, Madry, Radek, additional, Marth, Christian, additional, Putiri, Emily, additional, Barrett, Jamie, additional, DeMars, Leslie, additional, and Richardson, Debra, additional

Published
2022
Full Text
View/download PDF

270. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort

Author

Thomas, Quentin Dominique, primary, Boussere, Amal, additional, Classe, Jean-Marc, additional, Pomel, Christophe, additional, Costaz, Hélène, additional, Rodrigues, Manuel, additional, Ray-Coquard, Isabelle, additional, Gladieff, Laurence, additional, Rouzier, Roman, additional, Rouge, Thibault De La Motte, additional, Gouy, Sébastien, additional, Barranger, Emmanuel, additional, Sabatier, Renaud, additional, Floquet, Anne, additional, Marchal, Frédéric, additional, Guillemet, Cécile, additional, Polivka, Valentine, additional, Martin, Anne-Laure, additional, Colombo, Pierre-Emmanuel, additional, and Fiteni, Frédéric, additional

Published
2022
Full Text
View/download PDF

271. Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial

Author

Bonnet, Elise, primary, Haddad, Véronique, additional, Quesada, Stanislas, additional, Baffert, Kim-Arthur, additional, Lardy-Cléaud, Audrey, additional, Treilleux, Isabelle, additional, Pissaloux, Daniel, additional, Attignon, Valéry, additional, Wang, Qing, additional, Buisson, Adrien, additional, Heudel, Pierre-Etienne, additional, Bachelot, Thomas, additional, Dufresne, Armelle, additional, Eberst, Lauriane, additional, Toussaint, Philippe, additional, Bonadona, Valérie, additional, Lasset, Christine, additional, Viari, Alain, additional, Sohier, Emilie, additional, Paindavoine, Sandrine, additional, Combaret, Valérie, additional, Pérol, David, additional, Ray-Coquard, Isabelle, additional, Blay, Jean-Yves, additional, and Trédan, Olivier, additional

Published
2022
Full Text
View/download PDF

272. Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

Author

Borella, Fulvio, primary, Cosma, Stefano, additional, Ferraioli, Domenico, additional, Ray-Coquard, Isabelle, additional, Chopin, Nicolas, additional, Meeus, Pierre, additional, Cockenpot, Vincent, additional, Valabrega, Giorgio, additional, Scotto, Giulia, additional, Turinetto, Margherita, additional, Biglia, Nicoletta, additional, Fuso, Luca, additional, Mariani, Luca, additional, Franchi, Dorella, additional, Vidal Urbinati, Ailyn Mariela, additional, Pino, Ida, additional, Bertschy, Gianluca, additional, Preti, Mario, additional, Benedetto, Chiara, additional, Castellano, Isabella, additional, Cassoni, Paola, additional, and Bertero, Luca, additional

Published
2022
Full Text
View/download PDF

273. ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

Author

Borella, Fulvio, primary, Cosma, Stefano, additional, Ferraioli, Domenico, additional, Ray-Coquard, Isabelle, additional, Chopin, Nicolas, additional, Meeus, Pierre, additional, Cockenpot, Vincent, additional, Valabrega, Giorgio, additional, Scotto, Giulia, additional, Turinetto, Margherita, additional, Biglia, Nicoletta, additional, Fuso, Luca, additional, Mariani, Luca, additional, Franchi, Dorella, additional, Urbinati, Ailyn Mariela Vidal, additional, Pino, Ida, additional, Bertschy, Gianluca, additional, Preti, Mario, additional, Benedetto, Chiara, additional, Castellano, Isabella, additional, Cassoni, Paola, additional, and Bertero, Luca, additional

Published
2022
Full Text
View/download PDF

275. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study

Author

Joly, Florence, primary, Fabbro, Michel, additional, Berton, Dominique, additional, Lequesne, Justine, additional, Anota, Amélie, additional, Puszkiel, Alicja, additional, Floquet, Anne, additional, Vegas, Hélène, additional, Bourgeois, Hugues, additional, Bengrine Lefevre, Leïla, additional, You, Benoît, additional, Pommeret, Fanny, additional, Lortholary, Alain, additional, Spaeth, Dominique, additional, Hardy-Bessard, Anne-Claire, additional, Abdeddaim, Cyril, additional, Kaminsky-Forrett, Marie-Christine, additional, Tod, Michel, additional, Kurtz, Jean-Emmanuel, additional, Del Piano, Francesco, additional, Meunier, Jérôme, additional, Raban, Nadia, additional, Alexandre, Jérome, additional, Mouret-Reynier, Marie-Ange, additional, Ray-Coquard, Isabelle, additional, Provansal Gross, Magali, additional, and Brachet, Pierre-Emmanuel, additional

Published
2022
Full Text
View/download PDF

280. Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers

Author

Penel, Nicolas, Coindre, Jean‐Michel, Giraud, Antoine, Terrier, Philippe, Ranchere‐Vince, Dominique, Collin, Françoise, Guellec, Sophie L. E., Bazille, Céline, Lae, Marick, de Pinieux, Gonzague, Ray‐Coquard, Isabelle L., Bonvalot, Sylvie, Cesne, Axel L. E., Robin, Yves‐Marie, Stoeckle, Eberhardt, Toulmonde, Maud, and Blay, Jean‐Yves

Published
2018
Full Text
View/download PDF

283. Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.

Author

Christinat, Yann, Ho, Liza, Clément, Sophie, Genestie, Catherine, Sehouli, Jalid, Cinieri, Saverio, Gonzalez Martin, Antonio, Denison, Ursula, Fujiwara, Keiichi, Vergote, Ignace, Tognon, Germana, Hietanen, Sakari, Ray-Coquard, Isabelle, Pujade-Lauraine, Eric, and McKee, Thomas A.

Subjects
POLY ADP ribose, CLINICAL trials, OLAPARIB, BEVACIZUMAB, BIOMARKERS, OVERALL survival
Abstract

PURPOSE: The efficiency of the Myriad Homologous Recombination Deficiency (HRD) test to guide the use of poly (ADP-ribose) polymerase (PARP) inhibitors has been demonstrated in several phase III trials. However, a need exists for alternative clinically validated tests. METHODS: A novel biomarker for HRD was developed using The Cancer Genome Atlas database and, as part of the ENGOT HRD European Initiative, applied to 469 samples from the PAOLA-1/ENGOT-ov25 trial. Results were compared with the Myriad myChoice Genomic Instability Score (GIS) with respect to the progression-free survival in the olaparib + bevacizumab and placebo + bevacizumab arms. RESULTS: Analysis of the TCGA cohort revealed that a normalization of the number of large-scale state transitions by the number of whole-genome doubling events allows a better separation and classification of HRD samples than the GIS. Analysis of the PAOLA-1 samples, using the Geneva test (OncoScan + nLST), yielded a lower failure rate (27 of 469 v 59 of 469) and a hazard ratio of 0.40 (95% CI, 0.28 to 0.57) compared with 0.37 for Myriad myChoice (BRCAm or GIS+) in the nLST-positive samples. In patients with BRCAwt, the Geneva test identified a novel subpopulation of patients, with a favorable 1-year PFS (85%) but a poor 2-year PFS (30%) on olaparib + bevacizumab treatment. CONCLUSION: The proposed test efficiently separates HRD-positive from HRD-negative patients, predicts response to PARP inhibition, and can be easily deployed in a clinical laboratory for routine practice. The performance is similar to the available commercial test, but its lower failure rate allows an increase in the number of patients who will receive a conclusive laboratory result. PARP inhibitors, such as olaparib, have greatly improved survival of patients with ovarian carcinoma. The Geneva HRD test can predict response to olaparib in combination with bevacizumab. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

284. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network.

Author

Nigon, Elsa, Lefeuvre-Plesse, Claudia, Martinez, Alejandra, Chauleur, Céline, Lortholary, Alain, Favier, Laure, Bats, Anne-Sophie, Guille, Arnaud, AdélaÏde, José, Finetti, Pascal, de Casteljac, Victoire, Provansal, Magali, Mamessier, Emilie, Bertucci, François, Ray-Coquard, Isabelle, and Sabatier, Renaud

Subjects
RENAL cell carcinoma, COMPARATIVE genomics, HORMONE receptors, LYMPHADENECTOMY, EXTERNAL beam radiotherapy, UTERINE cancer, OCHRATOXINS
Abstract

Background: Uterine clear cell carcinomas (CCC) represent less than 5% of uterine cancers. Their biological characteristics and clinical management remain uncertain. A multicenter study to explore both clinical and molecular features of these rare tumors was conducted. Methods: This multicenter retrospective national study was performed within the French TMRG (Rare Gynecologic Malignant Tumors) network. Clinical data and, when available, FFPE blocks were collected. Clinical features, treatments, and outcome (progression-free survival (PFS) and overall survival (OS)) were analyzed and correlated to the protein (tissue micro-array), RNA (Nanostring nCounter® technology), and DNA (array-Comparative Genomic hybridization and target-next generation sequencing) levels using the tumor samples available. Results: Sixty-eight patients with uterine CCC were enrolled, 61 from endometrial localization and 5 with cervix localization. Median age at diagnosis was 68.9 years old (range 19–89.7). Most tumors were diagnosed at an early stage (78% FIGO stage I–II). Hysterectomy (performed in 90%) and lymph node dissection (80%) were the most frequent surgical treatment. More than 70% of patients received external beam radiotherapy and 57% received brachytherapy. Nearly half (46%) of the patients received chemotherapy. After a median follow-up of 24.7 months, median PFS was 64.8 months (95 CI [5.3–124.4]) and median OS was 79.7 (IC95 [31.0–128.4]). Low hormone receptor expression (13% estrogen-receptor positive), frequent PI3K pathway alterations (58% PTEN loss, 50% PIK3CA mutations), and P53 abnormalities (41%) were observed. Mismatch repair deficiency was identified in 20%. P16 expression was associated with shorter PFS (HR = 5.88, 95 CI [1.56–25], p = 0.009). Transcriptomic analyzes revealed a specific transcriptomic profile notably with a high expression of immune response-associated genes in uterine CCC displaying a very good overall prognosis. Conclusions: Uterine CCC reported to be potentially MSI high, hormone receptors negative, and sometimes TP53 mutated. However, some patients with immune response-associated features and better prognosis may be candidate to treatment de-escalation and immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

285. CREB fusion–associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotype.

Author

Trecourt, Alexis, Macagno, Nicolas, Ngo, Carine, Philip, Charles-André, Lopez, Jonathan, Ferreira, Joana, Alves-Vale, Catarina, Ray-Coquard, Isabelle, Genestie, Catherine, Agaimy, Abbas, and Devouassoux-Shisheboran, Mojgan

Abstract

EWSR1/FUS-CREB-rearranged mesenchymal neoplasms are an emerging heterogeneous group of soft tissue tumors that encompasses low-grade lesions (angiomatoid fibrous histiocytoma/AFH) and a group of predominantly intra-abdominal aggressive sarcomas with epithelioid morphology and frequent keratin expression. Both entities occasionally harbor EWSR1::ATF1 fusions as alternate to the more frequent EWSR1/FUS::CREB1/CREM fusions. Although EWSR1/FUS-CREB-rearranged epithelioid malignant neoplasms have been described in diverse intra-abdominal sites, none involved the female adnexa. Herein, we describe three cases involving uterine adnexa in young females (41, 39, and 42-year-old); two associated with constitutional inflammatory symptoms. The tumors presented as a serosal surface mass of the ovary without parenchymal involvement (Case 1), as circumscribed nodule within ovarian parenchyma (Case 2), and as a periadnexal mass extending into the lateral uterine wall with lymph node metastasis (Case 3). They were composed of sheets and nests of large epithelioid cells with numerous stromal lymphocytes and plasma cells. The neoplastic cells expressed desmin and EMA, and variably WT1. One tumor expressed in addition AE1/AE3, MUC4, synaptophysin, chromogranin, and ALK. None expressed sex cord-associated markers. RNA sequencing identified EWSR1::ATF1 fusions in two cases and an EWSR1::CREM fusion in one. Exome-based RNA capture sequencing and clustering methods showed high transcriptomic proximity of tumor 1 with soft tissue AFH. This novel subset of female adnexal neoplasms should be included in the differential diagnosis of any epithelioid neoplasm involving female adnexa. Their aberrant immunophenotype can be misleading, underlining a wide spectrum of differential diagnosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

286. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Author

Lebellec, Loïc, Bertucci, François, Tresch-Bruneel, Emmanuelle, Ray-Coquard, Isabelle, Le Cesne, Axel, Bompas, Emmanuelle, Blay, Jean-Yves, Italiano, Antoine, Mir, Olivier, Ryckewaert, Thomas, Toiron, Yves, Camoin, Luc, Goncalves, Anthony, Penel, Nicolas, and Le Deley, Marie-Cécile

Published
2018
Full Text
View/download PDF

287. Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

Author

Callens, Celine, Rodrigues, Manuel, Briaux, Adrien, Frouin, Eleonore, Eeckhoutte, Alexandre, Pujade-Lauraine, Eric, Renault, Victor, Stoppa-Lyonnet, Dominique, Bieche, Ivan, Bataillon, Guillaume, Karayan-Tapon, Lucie, Rochelle, Tristan, Heitz, Florian, Cecere, Sabrina Chiara, Pérez, Maria Jesús Rubio, Grimm, Christoph, Nøttrup, Trine Jakobi, Colombo, Nicoletta, Vergote, Ignace, Yonemori, Kan, Ray-Coquard, Isabelle, Stern, Marc-Henri, and Popova, Tatiana

Abstract

The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2-mutated (BRCAmut) and Homologous Recombination Deficient (HRD) high-grade Advanced Ovarian Cancer (AOC) first line setting, based on a significantly improved progression-free survival (PFS) compared to bev alone in the PAOLA-1/ENGOT-ov25 trial (NCT02477644), where HRD was detected by MyChoice CDx PLUS test. The academic shallowHRDv2test was developed based on shallow whole-genome sequencing as an alternative to MyChoice. Analytical and clinical validities of shallowHRDv2as compared to MyChoice on 449 PAOLA-1 tumor samples are presented. The overall agreement between shallowHRDv2and MyChoice was 94% (369/394). Less non-contributive tests were observed with shallowHRDv2(15/449; 3%) than with MyChoice (51/449; 11%). Patients with HRD tumors according to shallowHRDv2(including BRCAmut) showed a significantly prolonged PFS with bev+ola versus bev (median PFS: 65.7 versus 20.3 months, hazard ratio (HR): 0.36 [95% CI: 0.24–0.53]). This benefit was significant also for BRCA1/2wild-type tumors (40.8 versus 19.5 months, HR: 0.45 [95% CI: 0.26–0.76]). ShallowHRDv2is a performant, clinically validated, and cost-effective test for HRD detection.

Published
2023
Full Text
View/download PDF

288. Gynecological carcinosarcomas: Overview and future perspectives

Author

Collet, Laetitia, González López, Andrea María, Romeo, Clémence, Méeus, Pierre, Chopin, Nicolas, Rossi, Léa, Rowinski, Elise, Serre, Anne-Agathe, Rannou, Corrinne, Buisson, Adrien, Treilleux, Isabelle, and Ray-Coquard, Isabelle

Abstract

Gynecologic carcinosarcoma (CS) are rare and aggressive tumors composed of high-grade carcinoma and sarcoma. Carcinosarcoma account for less than 5% of uterine and ovarian carcinoma and patients have poor outcome with a 5-year overall survival of less than 30%. In early-stage setting, the treatment mainstay is surgery and adjuvant chemoradiotherapy or adjuvant chemotherapy in uterine (UCS) and ovarian CS (OCS), respectively. In metastatic or advanced stage disease, chemotherapy is the rule with a lower response rate and poorer prognosis compared to other high-grade carcinomas. Although very few treatment options are available, CS are often excluded from the clinical trials precluding therapeutic improvement. However, recent molecular advances are paving the way for new therapeutic strategies. In the current proposal, we extensively review the uterine and ovarian carcinosarcomas including epidemiology, pathology, genomic landscape, as well as current therapies and future perspectives.

Published
2023
Full Text
View/download PDF

289. Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor

Author

Ducarouge, Benjamin, Redavid, Anna-Rita, Victoor, Camille, Chira, Ruxanda, Fonseca, Aurélien, Hervieu, Maëva, Bergé, Roméo, Lengrand, Justine, Vieugué, Pauline, Neves, David, Goddard, Isabelle, Richaud, Mathieu, Laval, Pierre-Alexandre, Rama, Nicolas, Goldschneider, David, Paradisi, Andrea, Gourdin, Nicolas, Chabaud, Sylvie, Treilleux, Isabelle, Gadot, Nicolas, Ray-Coquard, Isabelle, Depil, Stéphane, Decaudin, Didier, Némati, Fariba, Marangoni, Elisabetta, Mery-Lamarche, Eliane, Génestie, Catherine, Tabone-Eglinger, Séverine, Devouassoux-Shisheboran, Mojgan, Moore, Kathryn J., Gibert, Benjamin, Mehlen, Patrick, and Bernet, Agnes

Abstract

Drug resistance and cancer relapse represent significant therapeutic challenges after chemotherapy or immunotherapy, and a major limiting factor for long-term cancer survival. Netrin-1 was initially identified as a neuronal navigation cue but has more recently emerged as an interesting target for cancer therapy, which is currently clinically investigated. We show here that netrin-1 is an independent prognostic marker for clinical progression of breast and ovary cancers. Cancer stem cells (CSCs)/Tumor initiating cells (TICs) are hypothesized to be involved in clinical progression, tumor relapse and resistance. We found a significant correlation between netrin-1 expression and cancer stem cell (CSC) markers levels. We also show in different mice models of resistance to chemotherapies that netrin-1 interference using a therapeutic netrin-1 blocking antibody alleviates resistance to chemotherapy and triggers an efficient delay in tumor relapse and this effect is associated with CSCs loss. We also demonstrate that netrin-1 interference limits tumor resistance to immune checkpoint inhibitor and provide evidence linking this enhanced anti-tumor efficacy to a decreased recruitment of a subtype of myeloid-derived suppressor cells (MDSCs) called polymorphonuclear (PMN)-MDSCs. We have functionally demonstrated that these immune cells promote CSCs features and, consequently, resistance to anti-cancer treatments. Together, these data support the view of both a direct and indirect contribution of netrin-1 to cancer stemness and we propose that this may lead to therapeutic opportunities by combining conventional chemotherapies and immunotherapies with netrin-1 interfering drugs.

Published
2023
Full Text
View/download PDF

290. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Author

Despierre, Evelyn, Vergote, Ignace, Anderson, Ryan, Coens, Corneel, Katsaros, Dionyssios, Hirsch, Fred R., Boeckx, Bram, Varella-Garcia, Marileila, Ferrero, Annamaria, Ray-Coquard, Isabelle, Berns, Els M. J. J., Casado, Antonio, Lambrechts, Diether, Jimeno, Antonio, and on behalf of the European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG), Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO), Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO), National Cancer Research Institute (NCRI), Australia New Zealand Gynaecological Oncology Group (ANZGOG), and the Mario Negri Gynecologic Oncology group (MaNGO)

Published
2015
Full Text
View/download PDF

291. Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma

Author

Christinat, Yann, primary, Ho, Liza, additional, Clément, Sophie, additional, Genestie, Catherine, additional, Sehouli, Jalid, additional, Martin, Antonio Gonzalez, additional, Denison, Ursula, additional, Fujiwara, Keiichi, additional, Vergote, Ignace, additional, Tognon, Germana, additional, Hietanen, Sakari, additional, Ray-Coquard, Isabelle, additional, Pujade-Lauraine, Eric, additional, and McKee, Thomas A., additional

Published
2022
Full Text
View/download PDF

292. Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

Author

Bini, Marta, primary, Quesada, Stanislas, additional, Meeus, Pierre, additional, Rodrigues, Manuel, additional, Leblanc, Eric, additional, Floquet, Anne, additional, Pautier, Patricia, additional, Marchal, Frédéric, additional, Provansal, Magali, additional, Campion, Loïc, additional, Causeret, Sylvain, additional, Gourgou, Sophie, additional, Ray-Coquard, Isabelle, additional, Classe, Jean-Marc, additional, Pomel, Christophe, additional, De La Motte Rouge, Thibault, additional, Barranger, Emmanuel, additional, Savoye, Aude Marie, additional, Guillemet, Cécile, additional, Gladieff, Laurence, additional, Demarchi, Martin, additional, Rouzier, Roman, additional, Courtinard, C, additional, Romeo, Clémence, additional, and Joly, Florence, additional

Published
2022
Full Text
View/download PDF

293. Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers

Author

Borella, Fulvio, primary, Cosma, Stefano, additional, Ferraioli, Domenico, additional, Ray-Coquard, Isabelle, additional, Chopin, Nicolas, additional, Meeus, Pierre, additional, Cockenpot, Vincent, additional, Valabrega, Giorgio, additional, Scotto, Giulia, additional, Turinetto, Margherita, additional, Biglia, Nicoletta, additional, Fuso, Luca, additional, Mariani, Luca, additional, Franchi, Dorella, additional, Vidal Urbinati, Ailyn Mariela, additional, Pino, Ida, additional, Bertschy, Gianluca, additional, Preti, Mario, additional, Benedetto, Chiara, additional, Castellano, Isabella, additional, Cassoni, Paola, additional, and Bertero, Luca, additional

Published
2022
Full Text
View/download PDF

294. A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305)

Author

Lee, Chee, primary, Gebski, Val, additional, Francis, Katherine, additional, Grenier, Julien, additional, Welz, Julia, additional, Mosconi, Anna Maria, additional, Rubio-Perez, Maria Jesús, additional, Grimm, Christoph, additional, Matsumoto, Takashi, additional, Vergote, Ignace, additional, Colombo, Nicoletta, additional, Mirza, Mansoor Raza, additional, FOLLANA, Philippe, additional, de Gregorio, Nikolaus, additional, Zamagni, Claudio, additional, García-García, Yolanda, additional, Meunier, Jérôme, additional, Pujade-Lauraine, Eric, additional, Friedlander, Michael, additional, and Ray-Coquard, Isabelle, additional

Published
2022
Full Text
View/download PDF

295. UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (585)

Author

Richardson, Debra, primary, Marth, Christian, additional, Banerjee, Susana, additional, Hays, John, additional, Arend, Rebecca, additional, Tseng, Jill, additional, Cibula, David, additional, Fidalgo, Jose Alejandro Perez, additional, Savarese, Antonella, additional, Madry, Radoslaw, additional, Pothuri, Bhavana, additional, Coleman, Robert, additional, Monk, Bradley, additional, Mirza, Mansoor, additional, Ray-Coquard, Isabelle, additional, Bernardo, Patricia, additional, Putiri, Emily, additional, Shahverdyan, Azniv, additional, Burger, Robert, additional, and Concin, Nicole, additional

Published
2022
Full Text
View/download PDF

296. Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319)

Author

Monk, Bradley, primary, Concin, Nicole, additional, Richardson, Debra, additional, Ray-Coquard, Isabelle, additional, Pothuri, Bhavana, additional, Marth, Christian, additional, Bernardo, Patricia, additional, Burger, Robert, additional, Im, Ellie, additional, Aldairy, Wassim, additional, Coleman, Robert, additional, and Mirza, Mansoor, additional

Published
2022
Full Text
View/download PDF

297. Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcoma

Author

Allignet, Benoît, primary, Waissi, Waisse, additional, Geets, Xavier, additional, Dufresne, Armelle, additional, Brahmi, Mehdi, additional, Ray-Coquard, Isabelle, additional, Blay, Jean-Yves, additional, Bouhamama, Amine, additional, Meeus, Pierre, additional, Vaz, Gualter, additional, Gouin, Francois, additional, Moncharmont, Coralie, additional, and Sunyach, Marie-Pierre, additional

Published
2022
Full Text
View/download PDF

298. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study

Author

Conforti, Fabio, primary, Gronchi, Alessandro, additional, Penel, Nicholas, additional, Jones, Robin L., additional, Broto, Javier M., additional, Sala, Isabella, additional, Bagnardi, Vincenzo, additional, Napolitano, Andrea, additional, Pala, Laura, additional, Pennacchioli, Elisabetta, additional, Catania, Chiara, additional, Queirolo, Paola, additional, Grigani, Giovanni, additional, Merlini, Alessandra, additional, Stacchiotti, Silvia, additional, Comandone, Alessandro, additional, Vincenzi, Bruno, additional, Quagliuolo, Vittorio, additional, Bertuzzi, Alexia, additional, Boglione, Antonella, additional, Palassini, Elena, additional, Baldi, Giacomo G., additional, Blay, Jean-Yves, additional, Ryckewaert, Thomas, additional, Toulmonde, Maud, additional, Italiano, Antoine, additional, Le Cesne, Axel, additional, Ray-Coquard, Isabelle, additional, Cruz, Josefina, additional, Hernández-León, Carmen N., additional, Trufero, Javier M., additional, da Silva Moura, David, additional, Muñiz, Nadia H., additional, and De Pas, Tommaso, additional

Published
2022
Full Text
View/download PDF

299. Refining Prognosis in Localized Gastrointestinal Stromal Tumor: Clinical Significance of Phosphatase and Tensin Homolog Low Expression and Gene Loss

Author

Feng, Xiaolan, primary, Li, Haocheng, additional, Fourquet, Joanna, additional, Brahmi, Mehdi, additional, Dufresne, Armelle, additional, Meurgey, Alexandra, additional, Ray-Coquard, Isabelle, additional, Wang, Qing, additional, Bollard, Julien, additional, Ducimetiere, Francoise, additional, Chibon, Frederic, additional, and Blay, Jean-Yves, additional

Published
2022
Full Text
View/download PDF

300. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Vergote, Ignace, primary, Gonzalez-Martin, Antonio, additional, Lorusso, Domenica, additional, Gourley, Charlie, additional, Mirza, Mansoor Raza, additional, Kurtz, Jean-Emmanuel, additional, Okamoto, Aikou, additional, Moore, Kathleen, additional, Kridelka, Frédéric, additional, McNeish, Iain, additional, Reuss, Alexander, additional, Votan, Bénédicte, additional, du Bois, Andreas, additional, Mahner, Sven, additional, Ray-Coquard, Isabelle, additional, Kohn, Elise C, additional, Berek, Jonathan S, additional, Tan, David S P, additional, Colombo, Nicoletta, additional, Zang, Rongyu, additional, Concin, Nicole, additional, O'Donnell, Dearbhaile, additional, Rauh-Hain, Alejandro, additional, Herrington, C Simon, additional, Marth, Christian, additional, Poveda, Andres, additional, Fujiwara, Keiichi, additional, Stuart, Gavin C E, additional, Oza, Amit M, additional, Bookman, Michael A, additional, Grimm, Christoph, additional, Berger, Regina, additional, Chang, Ting-Chang, additional, Ochiai, Kazunori, additional, Gebski, Val, additional, Davis, Alison, additional, Beale, Philip, additional, Vergote, Ignace, additional, Denys, Hannelore, additional, Vandecaveye, Vincent, additional, Candido dos Reis, Francisco Jose, additional, Del Pilar Estevez Diz, Maria, additional, Stuart, Gavin, additional, MacKay, Helen, additional, Carey, Mark, additional, Cibula, David, additional, Dundr (path), Pavel, additional, Dorigo, Oliver, additional, Berek, Jonathan, additional, Saadeh, Abu, additional, Boere, Ingrid, additional, Lok, Christianne, additional, Coronado, Pluvio, additional, Ottevanger, Nelleke, additional, Tan, David SP, additional, Ng, Joseph, additional, Gonzalez Martin, Antonio, additional, Oaknin, Ana, additional, Perez Fidalgo, Alejandro, additional, Lu, Karen, additional, López-Zavala, Carlos, additional, Gómez-García, Eva María, additional, Paoletti, Xavier, additional, Joly, Florence, additional, Bookman, Michael, additional, Arend, Rebecca, additional, Fujiwara, Hiroyuki, additional, Hasegawa, Kosei, additional, Bruchim, Ilan, additional, Tsoref, Dalia, additional, Oda, Katsutoshi, additional, Enomoto, Takayuki, additional, Michel, Dayana, additional, Kim, Hee-Seung, additional, Lee, Jung-Yun, additional, Mukhopadhyay, Asima, additional, Katsaros, Dionyssios, additional, Pignata, Sandro, additional, Scambia, Giovanni, additional, Kohn, Elise, additional, Lee, Jung-Min, additional, Nicum, Shibani, additional, Farrelly, Laura, additional, Sehouli, Jalid, additional, Keller, Maren, additional, Braicu, Elena, additional, Bjørge, Line, additional, Auranen, Annika, additional, Welch, Stephen, additional, Heinzelmann, Viola, additional, Roxburgh, Patricia, additional, Glasspool, Ros, additional, and Zhu, Jianqing, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results